- Home
- GLPG vs CUBI Comparison
GLPG vs CUBI Comparison
Compare GLPG & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | CUBI |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Belgium | United States |
| Employees | 704 | 790 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | CUBI |
|---|---|---|
| Price | $33.70 | $70.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $36.50 | ★ $86.33 |
| AVG Volume (30 Days) | 88.6K | ★ 400.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.24 |
| Revenue Next Year | N/A | $9.30 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $40.75 |
| 52 Week High | $37.78 | $82.56 |
Technical Indicators
Market Signals| Indicator | GLPG | CUBI |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 43.92 |
| Support Level | $31.88 | $64.84 |
| Resistance Level | $34.98 | $72.45 |
| Average True Range (ATR) | 0.76 | 2.77 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 32.98 | 48.65 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.